Therapeutics: Fibroblast growth factor receptor 1 (FGFR1; CD331); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); K-Ras (KRAS)

Cancer

INDICATION: Lung cancer; pancreatic cancer

Studies in cell culture and mice suggest combining FGFR1 inhibitors with the MEK1/MEK2 inhibitor Mekinist trametinib could help treat KRAS-mutant lung and pancreatic cancers.

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE